Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin.
Ontology highlight
ABSTRACT: Preclinical studies: Targeted lung cancer chemotherapy shows promiseWhen wrapped in an engineered vesicle and augmented with cancer-targeting peptides, chemotherapy drug doxorubicin shows increased efficacy in a preclinical study. Zhiyuan Zhong, from China’s Soochow University, and his team developed the therapeutic (cRGD-PS-Dox) that targets cancer cells that overexpress a specific protein (?v?3 integrin), such as those of non-small cell lung cancer. In vitro assays showed that cRGD-PS-Dox specifically targeted and inhibited cancer cells, and inhibited the growth and metastasis of human tumor grafts in mice. In vivo imaging confirmed a desirable drug stability profile and accumulation within tumors. These results showed clear advantages over non-targeted doxorubicin treatment controls. Mice treated with cRGD-PS-Dox also survived significantly longer than control-treated mice. The preferential attributes of the therapy make it a promising agent for further study into tumors that overexpress ?v?3 integrin.
SUBMITTER: Zou Y
PROVIDER: S-EPMC6292884 | biostudies-other | 2018
REPOSITORIES: biostudies-other
ACCESS DATA